Liver cancer diagnostics market seen reaching $14.75 billion by 2030

The Business Research Company says the liver cancer diagnostics market will grow from $10.32 billion in 2025 to $14.75 billion by 2030, driven by rising liver cancer cases, more imaging and molecular testing, and wider use of AI-enabled tools. North America was the largest regional market in 2025.

Why it matters: - Liver cancer diagnostics are central to earlier detection, treatment planning and tracking whether disease has spread beyond the liver. - Rising demand for testing reflects higher liver cancer incidence and broader adoption of advanced screening tools. - Growth in this market signals more spending on imaging, pathology, molecular testing and precision oncology diagnostics.

What happened: - The Business Research Company released its Liver Cancer Diagnostics Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report puts the market at $10.32 billion in 2025 and $11.07 billion in 2026. - The report projects the market will reach $14.75 billion by 2030. - The forecast implies a 7.3% compound annual growth rate from 2025 to 2026 and 7.4% through 2030. - North America was the largest regional market in 2025.

The details: - The market’s recent growth has been driven by higher rates of chronic liver disease, more hepatocellular carcinoma cases, expansion of hospital-based diagnostic facilities, greater awareness of early cancer screening, and better imaging and pathology technologies. - The report cites growing preference for precision oncology diagnostics, stronger demand for non-invasive tests, expanded molecular testing capacity, more funding for oncology research and wider use of AI-enhanced diagnostic platforms. - The report identifies several trends: advanced molecular diagnostic tests, improved imaging for early detection, broader biomarker-based screening, growth in personalized oncology diagnostics and stronger efforts to identify cancer at earlier stages. - Liver cancer diagnostics include imaging and molecular testing methods used to detect malignant disease originating in liver cells. - The report includes regional coverage of Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company also added market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - A free sample of the report is available. - The full market report is also available.

Between the lines: - The forecast suggests liver cancer diagnostics is shifting from a hospital-centric testing category toward a more data-driven market built around molecular tools, biomarkers and AI-assisted analysis. - The emphasis on non-invasive and precision diagnostics points to demand for tests that can identify disease earlier and reduce reliance on more invasive procedures. - The inclusion of detailed forecasting tools and scoring systems indicates the report is aimed as much at investors and strategists as at healthcare operators. - The American Cancer Society data in the release underscores why diagnostics demand remains tied to real-world incidence, not just technology adoption.

What's next: - The market is expected to keep expanding through 2030 as oncology research funding, molecular testing capacity and AI-enabled diagnostics continue to rise. - Wider adoption of biomarker-based screening and advanced imaging could accelerate earlier detection, which may support continued demand for liver cancer testing products and services. - Regional competition is likely to stay strongest in North America while other global markets continue to develop diagnostic infrastructure.

The bottom line: - Liver cancer diagnostics is a growing market with clear demand drivers, and the biggest opportunities appear tied to early detection, non-invasive testing and precision oncology.